The Inhibitory Effects of Anacardic Acid on Hepatitis C Virus Life Cycle

被引：21
作者：
Hundt, Jana [1 ]
Li, Zhubing [2 ]
Liu, Qiang [2 ]
机构：
[1] Univ Saskatchewan, VIDO InterVac, Saskatoon, SK, Canada
[2] Univ Saskatchewan, Vaccinol & Immunotherapeut Program, VIDO InterVac, Saskatoon, SK, Canada
来源：
PLOS ONE | 2015年 / 10卷 / 02期
关键词：
HISTONE ACETYLTRANSFERASE; CORE PROTEIN; SUMOYLATION; SUMO; APOPTOSIS; PRODUCTS; NUCLEAR; PATHWAY; ALPHA; ASSAY;
D O I：
10.1371/journal.pone.0117514
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Hepatitis C virus (HCV) is a small positive-sense single-stranded RNA virus that causes severe liver diseases. Current anti-HCV therapies involving direct-acting antivirals have significantly enhanced efficacy in comparison to traditional interferon and ribavirin combination. However, further improvement is needed to eradicate HCV. Anacardic acid (AnA) is a phytochemical compound that can inhibit the activity of various cellular enzymes including histone acetyltransferases (HATs). In this study, we investigated the effects of AnA on different phases of HCV life cycle. Our data showed that AnA can inhibit HCV entry, replication, translation, and virion secretion in a dose-dependent manner with no measurable effects on cell viability. In addition, we showed that two HAT inhibitors and knocking down HAT (PCAF) by RNAi can reduce HCV replication, suggesting a mechanism of AnA's inhibitory effects on HCV. Elucidation of the AnA-mediated inhibitory mechanism should facilitate the development of new drug candidates for HCV infection.
引用
收藏
页数：11
相关论文
共 45 条
[1]   HCV genetic variability: from quasispecies evolution to genotype classification [J].
Argentini, Claudio ;
Genovese, Domenico ;
Dettori, Stefano ;
Rapicetta, Maria .
FUTURE MICROBIOLOGY, 2009, 4 (03) :359-373
[2]   An overview of HCV molecular biology, replication and immune responses [J].
Ashfaq, Usman A. ;
Javed, Tariq ;
Rehman, Sidra ;
Nawaz, Zafar ;
Riazuddin, Sheikh .
VIROLOGY JOURNAL, 2011, 8
[3]   New Pharmacotherapy for Hepatitis C [J].
Assis, D. N. ;
Lim, J. K. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (03) :294-305
[4]   Small molecule modulators of histone acetyltransferase p300 [J].
Balasubramanyam, K ;
Swaminathan, V ;
Ranganathan, A ;
Kundu, TK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (21) :19134-19140
[5]   Host-targeting agents in the treatment of hepatitis C: A beginning and an end? [J].
Baugh, James M. ;
Garcia-Rivera, Jose A. ;
Gallay, Philippe A. .
ANTIVIRAL RESEARCH, 2013, 100 (02) :555-561
[6]   Forkhead Box Transcription Factor Regulation and Lipid Accumulation by Hepatitis C Virus [J].
Bose, Sandip K. ;
Kim, Hangeun ;
Meyer, Keith ;
Wolins, Nathan ;
Davidson, Nicholas O. ;
Ray, Ranjit .
JOURNAL OF VIROLOGY, 2014, 88 (08) :4195-4203
[7]   The hepatitis C virus 3′-untranslated region or a poly(A) tract promote efficient translation subsequent to the initiation phase [J].
Bradrick, SS ;
Walters, RW ;
Gromeier, M .
NUCLEIC ACIDS RESEARCH, 2006, 34 (04) :1293-1303
[8]   Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase [J].
Costi, Roberta ;
Di Santo, Roberto ;
Artico, Marino ;
Miele, Gaetano ;
Valentini, Paola ;
Novellino, Ettore ;
Cereseto, Anna .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (08) :1973-1977
[9]   Ginkgolic Acid Inhibits Protein SUMOylation by Blocking Formation of the E1-SUMO Intermediate [J].
Fukuda, Isao ;
Ito, Akihiro ;
Hirai, Go ;
Nishimura, Shinichi ;
Kawasaki, Hisashi ;
Saitoh, Hisato ;
Kimura, Ken-ichi ;
Sodeoka, Mikiko ;
Yoshida, Minoru .
CHEMISTRY & BIOLOGY, 2009, 16 (02) :133-140
[10]   PCAF Acetylates β-Catenin and Improves Its Stability [J].
Ge, Xinjian ;
Jin, Qihuang ;
Zhang, Fang ;
Yan, Tingting ;
Zhai, Qiwei .
MOLECULAR BIOLOGY OF THE CELL, 2009, 20 (01) :419-427
12345